EA201892510A2 - Комбинированная терапия для лечения рака - Google Patents

Комбинированная терапия для лечения рака

Info

Publication number
EA201892510A2
EA201892510A2 EA201892510A EA201892510A EA201892510A2 EA 201892510 A2 EA201892510 A2 EA 201892510A2 EA 201892510 A EA201892510 A EA 201892510A EA 201892510 A EA201892510 A EA 201892510A EA 201892510 A2 EA201892510 A2 EA 201892510A2
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
combined therapy
administering
pentaase
thioredoxin
Prior art date
Application number
EA201892510A
Other languages
English (en)
Other versions
EA201892510A3 (ru
Inventor
Роберт А. Беардсли
Деннис П. Райли
Джеффри Л. Кин
мл. Дуглас Р. Спитц
Мелисса А. Фэт
Original Assignee
ГАЛЕРА ЛЭБЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГАЛЕРА ЛЭБЗ, ЭлЭлСи filed Critical ГАЛЕРА ЛЭБЗ, ЭлЭлСи
Publication of EA201892510A2 publication Critical patent/EA201892510A2/ru
Publication of EA201892510A3 publication Critical patent/EA201892510A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Способ лечения рака у субъекта включает введение по меньшей мере одного активного агента, включая один или более из ингибитора тиоредоксинредуктазы и глутатион-истощающего агента, и введение макроциклического кольцевого комплекса пентааза, соответствующего формуле (I)
EA201892510A 2016-05-03 2017-05-03 Комбинированная терапия для лечения рака EA201892510A3 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662331253P 2016-05-03 2016-05-03
PCT/US2017/030871 WO2017192740A2 (en) 2016-05-03 2017-05-03 Combination therapy for cancer treatment

Publications (2)

Publication Number Publication Date
EA201892510A2 true EA201892510A2 (ru) 2019-06-28
EA201892510A3 EA201892510A3 (ru) 2019-09-30

Family

ID=60203338

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892510A EA201892510A3 (ru) 2016-05-03 2017-05-03 Комбинированная терапия для лечения рака

Country Status (14)

Country Link
US (1) US20190151331A1 (ru)
EP (1) EP3452060A4 (ru)
JP (2) JP2019514962A (ru)
KR (2) KR20230075528A (ru)
CN (1) CN109414454A (ru)
AU (2) AU2017260425B2 (ru)
BR (1) BR112018072560A2 (ru)
CA (1) CA3022699A1 (ru)
CL (1) CL2018003123A1 (ru)
EA (1) EA201892510A3 (ru)
IL (3) IL300085A (ru)
MX (1) MX2018013354A (ru)
SG (2) SG10202106462TA (ru)
WO (1) WO2017192740A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2056675T (lt) 2006-10-12 2019-05-27 Galera Labs, Llc Burnos gleivinės mukozito gydymo būdai
CN103906756B (zh) 2011-09-26 2020-03-03 加莱拉实验室有限责任公司 用于治疗疾病的方法
PL3334744T3 (pl) 2015-08-11 2020-09-21 Galera Labs, Llc Kompleksy pierścienia makrocyklicznego pentaaza posiadające biodostępność po podaniu doustnym
KR102388962B1 (ko) 2016-05-03 2022-04-27 바이엘 파마 악티엔게젤샤프트 방향족 술폰아미드 유도체
US11219614B2 (en) 2016-09-01 2022-01-11 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
WO2019098288A1 (ja) * 2017-11-15 2019-05-23 学校法人 慶應義塾 抗腫瘍剤及び配合剤
WO2019104579A1 (en) * 2017-11-30 2019-06-06 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
GB201800733D0 (en) * 2018-01-17 2018-02-28 Cambridge Entpr Ltd Cancer
JP2019131508A (ja) * 2018-01-31 2019-08-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
JP2021512110A (ja) * 2018-01-31 2021-05-13 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
WO2019232648A1 (en) * 2018-06-08 2019-12-12 Atomic Energy Of Canada Limited / Énergie Atomique Du Canada Limitée Use of a checkpoint inhibitor in combination with ultralow dose whole body irradiation
CN109620836B (zh) * 2018-12-24 2021-05-18 陕西科技大学 一种具有抗乳腺癌作用的复方药物组合物及其用途和基于此组合物的药物
WO2021050490A1 (en) * 2019-09-13 2021-03-18 The Trustees Of Columbia University In The City Of New York Methods of enhancing radiotherapy using ferroptosis inducers as radiosensitizers
CN114502179A (zh) * 2019-10-10 2022-05-13 加莱拉实验室有限责任公司 含锰配合物的水性制剂的制备方法、制剂和治疗方法
WO2021247714A1 (en) * 2020-06-02 2021-12-09 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent
US20230265108A1 (en) * 2020-07-29 2023-08-24 University Of Kentucky Research Foundation Gold(iii) compounds and cancer cell-selective modulation of mitochondrial respiration and metabolism
WO2024026273A1 (en) * 2022-07-25 2024-02-01 Galera Labs, Llc Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296645B1 (en) * 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
JP5779503B2 (ja) * 2008-10-29 2015-09-16 イスティチュート スペリオーレ ディ サニータ 酸化ストレスを用いるレトロウイルスレゼルボアの処置
CN103906756B (zh) * 2011-09-26 2020-03-03 加莱拉实验室有限责任公司 用于治疗疾病的方法

Also Published As

Publication number Publication date
AU2023204318A1 (en) 2023-07-27
EA201892510A3 (ru) 2019-09-30
JP2019514962A (ja) 2019-06-06
AU2017260425A1 (en) 2018-11-22
IL262661A (en) 2018-12-31
EP3452060A4 (en) 2020-01-01
KR20230075528A (ko) 2023-05-31
AU2017260425B2 (en) 2023-04-06
EP3452060A2 (en) 2019-03-13
IL290149A (en) 2022-03-01
SG10202106462TA (en) 2021-07-29
MX2018013354A (es) 2019-02-20
IL300085A (en) 2023-03-01
KR20180132939A (ko) 2018-12-12
IL262661B (en) 2022-03-01
WO2017192740A2 (en) 2017-11-09
JP2023036950A (ja) 2023-03-14
CA3022699A1 (en) 2017-11-09
BR112018072560A2 (pt) 2019-02-19
CL2018003123A1 (es) 2019-05-03
SG11201809606YA (en) 2018-11-29
US20190151331A1 (en) 2019-05-23
CN109414454A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
EA201892510A2 (ru) Комбинированная терапия для лечения рака
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CO2017006230A2 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201890159A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
PH12015502549B1 (en) Heterocyclic derivatives
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX362806B (es) Inhibidores biciclicos.
TW201613578A (en) Pharmaceutical combinations
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
WO2018045348A3 (en) ANTICANCER POLY THERAPY WITH PENTAAZA MACROCYCLIC CYCLE COMPLEX AND ASCORBATE COMPOUND
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EA201792286A1 (ru) Способы лечения рака
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica